Changes in the treatment of metastatic prostate cancer-new data and open questions

被引：0

作者：

Albers, P. ^{[1
,2
]}

Boegemann, M. ^{[3
]}

Machtens, S. ^{[4
]}

Merseburger, A. S. ^{[5
]}

Schostak, M. ^{[6
]}

Steuber, T. ^{[7
]}

Wuelfing, C. ^{[8
]}

De Santis, M. ^{[9
]}

机构：

[1] Heinrich Heine Univ, Univ Klinikum, Klin Urol, Med Fak,Comprehens Canc Ctr, Moorenstr 5, D-40225 Dusseldorf, Germany

[2] Heinrich Heine Univ, Univ Tumorzentrum, Moorenstr 5, D-40225 Dusseldorf, Germany

[3] Univ Klinikum Munster, Klin Urol & Kinderurol, Munster, Germany

[4] Marien Krankenhaus, Klin Urol & Kinderurol, Betriebsstatte, GFO Kliniken Rhein Berg, Bergisch Gladbach, Germany

[5] Univ Klinikum Schleswig Holstein, Klin Urol, Campus Lubeck, Lubeck, Germany

[6] Univ Klinikum Magdeburg, Klin Urol & Kinderurol, Magdeburg, Germany

[7] Univ Klinikum Hamburg Eppendorf, Prostatakrebszentrum, Martini Klin, Hamburg, Germany

[8] Asklepios Klin Altona, Abt Urol, Hamburg, Germany

[9] Charite Univ Med Berlin, Klin Urol, Interdisziplinare Uroonkol, Berlin, Germany

来源：

UROLOGE | 2020年 / 59卷 / 03期

关键词：

Androgen receptor; Prostatic neoplasms; castration-naive; Chemotherapy; Oligometastases; Systemic therapy; ANDROGEN DEPRIVATION THERAPY; INCREASED SURVIVAL; MEN; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; CABAZITAXEL; APALUTAMIDE; ABIRATERONE; PREDNISONE;

D O I：

10.1007/s00120-019-01072-0

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.

引用

页码：307 / 317

页数：11

共 50 条

[1] Treatment of metastatic prostate cancer:: recognized facts and open questions
Fournier, G
Valéri, A
[J]. PRESSE MEDICALE, 1998, 27 (38): : 1996 - 2002
[2] Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene FragenChanges in the treatment of metastatic prostate cancer—new data and open questions
P. Albers
M. Bögemann
S. Machtens
A. S. Merseburger
M. Schostak
T. Steuber
C. Wülfing
M. De Santis
[J]. Der Urologe, 2020, 59 (3): : 307 - 317
[3] New Aspects in Treatment of Metastatic Prostate Cancer
von Amsberg, Gunhild
Bokemeyer, Carsten
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (15) : 1106 - 1110
[4] HORMONE-REFRACTORY PROSTATE CANCER-NEW OPTIONS FOR ITS MANAGEMENT
Holubec, L.
Klecka, J.
Topolcan, O.
Pesta, M.
Eret, V.
Finek, J.
Hora, M.
[J]. ANTICANCER RESEARCH, 2008, 28 (5C) : 3319 - 3319
[5] Surgical treatment of esophageal cancer-New technologies, modern concepts
Schmidt, Thomas
Babic, Benjamin
Bruns, Christiane J.
Fuchs, Hans F.
[J]. CHIRURG, 2021, 92 (12): : 1100 - 1106
[6] New treatment options for patients with metastatic prostate cancer
Snoeks, L. L.
Ogilvie, A. C.
van Haarst, E. P.
Siegert, C. E. H.
[J]. NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (06): : 290 - 294
[7] Treatment of metastatic prostate cancer
Gilson, Clare
Manickavasagar, Thubeena
Chowdhury, Simon
[J]. TRENDS IN UROLOGY & MENS HEALTH, 2015, 6 (04) : 7 - 12
[8] TREATMENT OF METASTATIC CANCER OF THE PROSTATE
FOURNIER, G
MANGIN, P
[J]. PRESSE MEDICALE, 1995, 24 (32): : 1465 - &
[9] New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer
Festuccia, Claudio
Negri-Cesi, Paola
Gravina, Giovanni Luca
[J]. CURRENT DRUG TARGETS, 2016, 17 (03) : 254 - 256
[10] Current Data confirms the Benefit of Zytiga® in the Treatment of metastatic Prostate Cancer
不详
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 422 - 422

← 1 2 3 4 5 →